Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ADAMTS5 | Q9UNA0 | 2/20 | 0.45 |
| ▸ | NPC1L1 | Q9UHC9 | 5/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.43 |
| ▸ | TACR1 | P25103 | 4/20 | 0.42 |
| ▸ | CCR1 | P32246 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2309876 | 0.89 | CHRM2 (0.46) | RAB9AALDH1A1GAAADAMTS5NPC1L1 | |
| SCHEMBL2309856 | 0.85 | LMNA (0.44) | RAB9AALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL2311931 | 0.85 | OPRM1 (0.42) | ALDH1A1MAPTCHRM4 | |
| SCHEMBL2311920 | 0.84 | PPID (0.42) | ALDH1A1MAPT | |
| SCHEMBL2312630 | 0.84 | CPT1A (0.42) | ALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL2310630 | 0.84 | ALDH1A1 (0.45) | ALDH1A1MAPTSMN1; SMN2ADAMTS5NPC1L1 | |
| SCHEMBL2312344 | 0.83 | ALDH1A1 (0.54) | RAB9AALDH1A1GAAMAPTSMN1; SMN2 | |
| SCHEMBL2307336 | 0.82 | CHRM4 (0.48) | RAB9AGAAADAMTS5CHRM4TACR1 | |
| SCHEMBL2313548 | 0.82 | ALDH1A1 (0.44) | RAB9AALDH1A1GAANPC1L1TACR1 | |
| SCHEMBL2310367 | 0.82 | FNTA (0.40) | MAPTCHRM4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | claimed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | claimed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | claimed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | claimed |
| US-8044069-B2 | Compounds as calcium channel blockers | ABBOTT LABORATORIES (US) | 2011-10-25 | — | — | US | disclosed |
| EP-2350002-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | Abbott Laboratories (US) | 2011-08-03 | — | — | EP | disclosed |
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-15 | — | — | US | disclosed |
| WO-2010039947-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ABBOTT LABORATORIES (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093730-A1 | NOVEL COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1E, CACNA1S, CACNA1D | RAB9A 1812/4885ALDH1A1 1622/4885GAA 3281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.